Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Short Interest Update

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totaling 29,166,975 shares, an increase of 161.6% from the December 31st total of 11,149,487 shares. Based on an average daily trading volume, of 84,020,039 shares, the days-to-cover ratio is presently 0.3 days. Approximately 1,462.7% of the company’s shares are short sold. Approximately 1,462.7% of the company’s shares are short sold. Based on an average daily trading volume, of 84,020,039 shares, the days-to-cover ratio is presently 0.3 days.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ASBP. CIBC Bancorp USA Inc. purchased a new stake in Aspire Biopharma during the 3rd quarter worth approximately $28,000. Jane Street Group LLC grew its stake in shares of Aspire Biopharma by 625.8% in the second quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock worth $41,000 after acquiring an additional 131,533 shares in the last quarter. Optivise Advisory Services LLC grew its stake in shares of Aspire Biopharma by 120.9% in the second quarter. Optivise Advisory Services LLC now owns 235,106 shares of the company’s stock worth $63,000 after acquiring an additional 128,660 shares in the last quarter. Finally, Crewe Advisors LLC increased its position in shares of Aspire Biopharma by 100.0% during the second quarter. Crewe Advisors LLC now owns 626,854 shares of the company’s stock worth $169,000 after acquiring an additional 313,427 shares during the period. Hedge funds and other institutional investors own 19.17% of the company’s stock.

Aspire Biopharma Stock Down 8.2%

NASDAQ:ASBP opened at $1.46 on Friday. Aspire Biopharma has a 52 week low of $1.41 and a 52 week high of $632.00. The stock’s fifty day moving average is $3.60 and its two-hundred day moving average is $11.09. The stock has a market capitalization of $3.93 million, a price-to-earnings ratio of -0.07 and a beta of 0.81.

Aspire Biopharma (NASDAQ:ASBP) last posted its quarterly earnings data on Friday, November 14th. The company reported ($1.60) earnings per share (EPS) for the quarter. The company had revenue of $0.00 million during the quarter.

Wall Street Analyst Weigh In

A number of analysts have issued reports on ASBP shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aspire Biopharma in a research note on Wednesday, January 21st. Wall Street Zen raised shares of Aspire Biopharma to a “sell” rating in a research note on Saturday, January 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Aspire Biopharma Company Profile

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.